PBT2 for Middle Ear Infections, page-20

It’s hard to know for sure what vision the company is lacking without hearing managements position on PBT2 straight from their mouth.

I personally see pbt2 as a backup plan given I invested in Ath for 2 reasons, though one of those reasons has recently been impacted.

let’s just get 343 trials started before we make assumptions on what the company is or is not doing with pbt2. I’ve mentioned before that the company was doing F-all with pbt2 yet we have posters still banging on about pbt2. It’s an absurd distraction right now from the company’s sole objective. There is tons of risk already riding on 434 so de-risking that should be number 1 priority. If UQ intends to fast forward any work to commercialise pbt2 then power to them. However Ath at present does not have the time, money, experience, not personnel to allocate into pbt2. I will assume all work on it is being done by UQ until stated otherwise by the company.

Perhaps pivalde can call UQ and ask about pbt2 as I could care less about what’s happening with it given we still have not commenced P2 for 434. If investors wish to allocate their time into pbt2 then good for them. As for the majority of investors, we continue to await any type of return from the progress made on 434.

gltah abd dyor